Document is current
Any future updates will be listed below
-
Authors
Beltrán, Jacqueline M. https://orcid.org/0000-0001-6311-9947
Jacob, Yael
Mehta, Marishka M. https://orcid.org/0000-0001-5105-6723
Hossain, Tasnim
Adams, Abigail
Fontaine, Samantha
Torous, John https://orcid.org/0000-0002-5362-7937
McDonough, Catherine
Johnson, Matthew
Delgado, Andrew D.
Murrough, James W. https://orcid.org/0000-0001-6286-1242
Morris, Laurel S.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K01MH12043)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR004419)
The Friedman Brain Institute, The Ehrenkranz Laboratory for Human Resilience, The Gottesman Foundation
- License Information
-
More Information
Article History
Received: 12 August 2024
Accepted: 24 April 2025
First Online: 10 May 2025
Competing interests
: Murrough has provided consultation services for Allergan Pharmaceuticals (AbbVie), Biohaven Pharmaceuticals, Inc., Boehreinger Ingelheim Inc., Cliniclabs, Inc., Clexio Biosciences, Ltd., Compass Pathfinder, Plc., Engrail Therapeutics, Inc., Fortress Biotech, FSV7, Llc., Genentech, Impel Neuropharma, Janssen Pharmaceuticals, KetaMed, Inc., LivaNova, Plc., Merck & Co., Inc., Novartis, Otsuka Pharmaceutical, Ltd., Sage Therapeutics, WCG, and Xenon Pharmaceuticals, Inc. Torous serves as an editor for npj Digital Medicine.
